|
|
The Cardiovascular Market Outlook To 2010Published by: Business Insights Published: Oct. 1, 2005 - 174 Pages Table of ContentsTable of Contents The Cardiovascular Market Outlook to 2010 Executive summary 10 Patient potential 10 Global cardiovascular market analysis 11 Leading players in the cardiovascular market 12 Analysis of potential future cardiovascular blockbusters 13 Chapter 1 Patient potential 16 Summary 16 Introduction 17 Disease description 17 Defining patient potential 19 Limitations of cardiovascular epidemiology data 19 Cardiovascular risk factors 20 Hypertension 20 Prevalence 23 Factors driving prevalence 24 Forecast prevalence of hypertension in the seven major markets 25 Dyslipidemia 26 Prevalence 29 Factors driving prevalence 30 Forecast prevalence of dyslipidemia 31 Diabetes 32 Cardiovascular disease 35 Prevalence 36 Acute thrombotic events 38 Acute coronary syndromes 38 ST-segment elevation myocardial infarction (STEMI)/acute MI 40 Unstable angina and NSTEMI 41 Venous thromboembolism 44 Stroke 46 Cardiovascular procedures 48 4 Chapter 2 Global cardiovascular market analysis 52 Summary 52 Introduction 53 Market breakdown by therapy area 53 Leading products 56 Anti-hypertensives 57 Introduction 57 Analysis of the top 10 anti-hypertensives 60 Market analysis by drug class 62 ACE inhibitors 62 Calcium channel blockers 68 Angiotensin receptor blockers 71 Beta blockers 78 Diuretics 80 Other hypertension drugs 82 Anti-hypertensives sales forecasts 82 Anti-dyslipidemics 84 Introduction 84 Top 10 anti-dyslipidemics 85 Market analysis by drug class 87 Statins 87 Fibrates 90 Non-statin products 91 Other anti-dyslipidemics 92 Anti-dyslipidemic sales forecasts 92 Anti-thrombotics 93 Introduction 93 Top 10 anti-thrombotics 96 Market analysis by drug class 98 Anti-platelets 98 Heparins 101 Vitamin K antagonists 104 Fibrinolytics 106 Anti-thrombotics sales forecasts 107 Cardiac Therapies 108 Introduction 108 Top 10 cardiac therapies 110 Market analysis by drug class 110 Other cardiac therapies 110 Nitrites and nitrates 112 Anti-arrhythmics 113 Cardiac therapies sales forecasts 113 5 Chapter 3 Leading players in the cardiovascular market 116 Summary 116 Introduction 117 Global market shares 117 Pfizer 119 Marketed products 120 R&D compounds 121 Cardiovascular portfolio sales forecasts 122 Merck & Co. 123 Marketed products 123 R&D compounds 124 Cardiovascular portfolio sales forecasts 125 Bristol-Myers Squibb 126 Marketed products 126 R&D compounds 127 Cardiovascular portfolio sales forecasts 128 Novartis 129 Marketed products 129 R&D compounds 130 Cardiovascular portfolio sales forecasts 131 AstraZeneca 132 Marketed products 132 R&D compounds 133 Cardiovascular portfolio sales forecasts 134 Sanofi-Aventis 135 Marketed products 135 R&D compounds 136 Cardiovascular portfolio sales forecasts 137 Chapter 4 Analysis of potential future cardiovascular blockbusters 140 Summary 140 Introduction 141 Drug profiles 142 AGI-1067 142 Caduet 144 Exanta (ximelagatran/melagatran) 145 Idraparinux 148 LY-674 150 NKS-104/Livalo (pitavastatin) 151 Pactimibe 153 6 Ranexa (ranolazine) 155 SPP100 (aliskiren) 157 Thelin (sitaxsentan) 160 torcetrapib and torcetrapib/atorvastatin 162 480848 164 Chapter 5 Appendix 168 IMS sales figures 168 Glossary 169 Index 171 List of Figures Figure 1.1: Relationship between cardiovascular disease and risk factors 18 Figure 1.2: Proportion of hypertension sufferers which have controlled hypertension 22 Figure 1.3: Risk factors associated with hypertension 24 Figure 2.4: Competitive dynamics in the global cardiovascular market, 55 Figure 2.5: Competitive dynamics in the global anti-hypertensives market by class, 2003-04 58 Figure 2.6: Competitive dynamics of the top ten anti-hypertensives by drug class, 2002-03 61 Figure 2.7: Competitive dynamics in the global anti-dyslipidemics market by leading brands, 2003-04 86 Figure 2.8: Competitive dynamics in the global anti-thrombotics market, 2003-04 95 Figure 2.9: Competitive dynamics in the global anti-thrombotics market by leading brands, 2003- 04 97 Figure 2.10: Competitive dynamics in the global cardiac therapies market, 2003-04 109 Figure 3.11: Key players in the global cardiovascular market, 2000 & 2004 119 Figure 4.12: High potential drugs in late-stage development or that have been recently launched141 Figure 4.13: Forecast sales of AGI-1067 143 Figure 4.14: Forecast sales of Caduet, 2005-2010 145 Figure 4.15: Forecast sales of Exanta 147 Figure 4.16: Forecast sales of idraparinux, 2005-2010 149 Figure 4.17: Forecast sales of NKS-104 153 Figure 4.18: Forecast sales of pactimibe, 2005-2010 155 Figure 4.19: Forecast sales of Ranexa, 2005-2010 157 Figure 4.20: Forecast sales of SPP-100 159 Figure 4.21: Forecast sales of Thelin, 2005-2010 162 Figure 4.22: Forecast sales of torcetrapib/Lipitor 164 Figure 4.23: Forecast sales of 480848 166 7 List of Tables Table 1.1: Prevalence of hypertension in the seven major markets, 2004 23 Table 1.2: Estimated prevalence of hypertension in the seven major markets, 2005-10 25 Table 1.3: Clinical guidelines for adult patients at borderline and high risk of cardiovascular disease by serum levels of lipids 28 Table 1.4: Prevalence of hypercholesterolemia in the seven major markets, 2004 29 Table 1.5: Estimated prevalence of hypercholesterolemia in the seven major markets, 2005-10 31 Table 1.6: Estimated prevalence of diabetes in the seven major markets, 2004 33 Table 1.7: Estimated prevalence of diabetes in the seven major markets, 2005-10 34 Table 1.8: Estimated prevalence of major cardiovascular diseases in the seven major markets, 2004 37 Table 1.9: Estimated incidence of ACS in the seven major markets, 2004 39 Table 1.10: Estimated incidence of STEMI in the seven major markets, broken down by age, 2004 40 Table 1.11: Estimated incidence of NSTEMI in the seven major markets, broken down by age, 2004 42 Table 1.12: Estimated incidence of UA in the seven major markets, broken down by age, 2004 43 Table 1.13: Estimated incidence of VTE in the seven major markets, 2004 45 Table 1.14: Prevalence of stroke in the seven major markets, 2004 47 Table 1.15: Estimated incidence of cardiovascular procedures in the seven major markets, 2004 49 Table 2.16: Global sales of key cardiovascular therapy areas, 2000-2004 53 Table 2.17: Global top 10 selling cardiovascular products, 2004 56 Table 2.18: Breakdown of the global anti-hypertensives market by drug class, 2003-04 57 Table 2.19: Breakdown of the global anti-hypertensives market by leading brands, 2003-04 60 Table 2.20: Breakdown of the global ACE inhibitor market by leading brands, 2003-04 63 Table 2.21: Breakdown of the global CCB market by leading brands, 2003-04 69 Table 2.22: Breakdown of the global ARB market by leading brands, 2003-04 73 Table 2.23: Breakdown of the global beta-blocker market by leading brands, 2003-04 78 Table 2.24: Breakdown of the global diuretics market by leading brands, 2003-04 81 Table 2.25: Global sales forecasts for drug classes within the anti-hypertensives market, 2004-10 82 Table 2.26: Breakdown of the global anti-dyslipidemics market by drug class, 2003-04 84 Table 2.27: Breakdown of the global anti-dyslipidemics market by leading brands, 2003-04 85 Table 2.28: Global sales forecasts for drug classes within the anti-dyslipidemics market, 2004-10 92 Table 2.29: Breakdown of the global anti-thrombotics market by drug class, 2003-04 93 Table 2.30: Breakdown of the global anti-thrombotics market by leading brands, 2003-04 96 Table 2.31: Breakdown of the global anti-platelets market by leading brands, 2003-04 99 Table 2.32: Breakdown of the global heparin market by leading brands, 2003-04 102 Table 2.33: Global sales forecasts for drug classes within the anti-thrombotics market, 2004-10 107 Table 2.34: Breakdown of the global cardiac therapies market by drug class, 2003-04 108 Table 2.35: Breakdown of the global cardiac therapies market by leading brands, 2003-04 110 Table 2.36: Global sales forecasts for drug classes within the anti-dyslipidemics market, 2004-10 114 Table 3.37: Key players in the global cardiovascular market, 2000-2004 117 Table 3.38: Pfizer’s marketed cardiovascular portfolio, 2004 120 Table 3.39: Pfizer’s cardiovascular R&D pipeline, 2005 121 8 Table 3.40: Forecast sales for Pfizer’s cardiovascular portfolio, 2004-10 122 Table 3.41: Merck & Co.’s marketed cardiovascular portfolio, 2004 123 Table 3.42: Merck’s cardiovascular R&D pipeline, 2004 124 Table 3.43: Forecast sales for Merck’s cardiovascular portfolio, 2004-10 125 Table 3.44: Bristol-Myers Squibb’s marketed cardiovascular portfolio, 2004 126 Table 3.45: Bristol-Myers Squibb’s cardiovascular R&D pipeline, 2005 127 Table 3.46: Forecast sales for Bristol-Myers Squibb’s cardiovascular portfolio, 2004-10 128 Table 3.47: Novartis’ marketed cardiovascular portfolio, 2004 129 Table 3.48: Novartis’ cardiovascular R&D pipeline, 2005 130 Table 3.49: Forecast sales for Novartis’ cardiovascular portfolio, 2004-09 131 Table 3.50: AstraZeneca’s marketed cardiovascular portfolio, 2004 132 Table 3.51: AstraZeneca’s cardiovascular R&D pipeline, 2004 133 Table 3.52: Forecast sales for AstraZeneca’s cardiovascular portfolio, 134 Table 3.53: Sanofi-Aventis’ marketed cardiovascular portfolio, 2004 135 Table 3.54: Sanofi-Aventis’ cardiovascular R&D pipeline, 2004 136 Table 3.55: Forecast sales for Sanofi-Aventis’ cardiovascular portfolio, 2005-10 137 AbstractThe range of conditions within cardiovascular disease is wide, although the basic etiology of cardiovascular disease is generally well understood the focus on treatment in cardiovascular disease is twofold: firstly lowering the risk associated with cardiovascular risk factors in order to prevent an acute cardiovascular event; and secondly delaying or preventing the onset of chronic cardiovascular disease. This report provides information on the prevalence and incidence of cardiovascular disease in the seven largest pharmaceutical markets in 2004, and provides forecast epidemiological data for major therapeutic indications over the period 2004 to 2010.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||